What are your top takeaways in GI Cancers from ASCO 2026?

• LBA 5, RASolute302 study: The daraxonrasib plenary, hands down, is the most important GI oncology study at ASCO. I would argue it’s probably one of the most important studies in oncology since immunotherapy. This showed an oral pan-RAS inhibitor doubled survival for second-line treatment of metasta...

Here are my top 3 presentations/studies in GI cancers from the ASCO 2026 annual meeting.

1. Daraxonrasib (RASolute 302) Study

Daraxonrasib (RMC-6236) was arguably the most practice-changing therapy presented at the 2026 ASCO Annual Meeting for pancreatic cancer. Daraxonrasib is a first-in-class, ora...

Daraxonrasib will change the treatment paradigm for PDAC indefinitely, with implications across all stages.

This year, in GI onc, there was RASolute 302 — and then there was everything else. Patients with pancreatic cancer have been waiting decades for a key that would begin to unlock the door to molecularly targeted therapy for this dreaded disease. The desire for this was so ardent that the POLO trial w...

I may have a few biases here!

• RASolute 302
• EMERALD-3 trial
• BREAKWATER update

1. Daraxonrasib, a Ras(ON) multi-selective inhibitor vs chemotherapy in previously treated mPDAC: Primary and final analysis from the phase 3 RASolute 302 study by Dr. Wolpin (Dana-Farber).
   • Why this was impactful: This earned a standing ovation and is practice-changing because daraxonrasib showed unp...